By Heather Landi
Leading healthcare experts released a report this week outlining major policy recommendations to support the expanded use of telehealth in the wake of the COVID-19 pandemic. Here's why one physician group says the task force recommendations don't go far enough to support independent doctors.
read more
By Ben Adams
The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder, especially after AstraZeneca’s trial was briefly stopped in the U.K. (and is still on hold in the U.S.).
read more
By Kyle Blankenship
With the fourth quarter fast approaching, it's do-or-die time for a group of drugmakers' chasing the first approved vaccine for COVID-19. Sanofi and GlaxoSmithKline are running a bit behind other companies in terms of clinical testing, but that doesn't mean they aren't ready to sign their own momentous supply deals.
read more
By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner
Russia approved two generic versions of Fujifilm's Avigan to treat COVID-19. HHS Secretary Alex Azar spearheaded last month's push to strip the FDA's oversight on lab-developed tests, Politico reported. Patchy data on antigen testing has obscured the true number of U.S. COVID-19 infections. And clinical trial suspensions are on the upswing once more, Phesi found.
read more
By Heather Landi
Telehealth company Amwell saw its stock spike 42% in its first day of trading Thursday after raising an outsized initial public offering. The company's public debut may serve as a barometer for the telehealth market, which has seen business surge as the COVID-19 pandemic drives huge demand for remote care services.
read more
By Beth Snyder Bulik
It's a once-in-a-generation opportunity for the pharma industry to rehabilitate its reputation as the COVID-19 pandemic swings consumer opinion. But while the door is open to long-term image repair, one expert warns pharma companies have to make real changes in the way they present themselves.
read more
By Paige Minemyer
CareFirst BlueCross BlueShield and MedStar Health are teaming up to launch a value-based care initiative they say could save $400 million over the next seven years.
read more
